TTN and thymoma: In addition, the rate of patients who received systemic chemotherapy was higher in the titin+ group (38.7%) than in the titin– group (6.1%, p = 0.002), as the proportion of patients who experienced thymoma recurrence (32.2 vs. 9.1%, p = 0.030).